General
Preferred name
TETOMILAST
Synonyms
OPC-6535 ()
P&D ID
PD008626
CAS
145739-56-6
Tags
available
drug candidate
Drug Status
investigational
Max Phase
3.0
Drug indication
Chronic obstructive pulmonary disease
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Tetomilast (OPC-6535) is a PDE4 inhibitor with potential for the research of inflammatory bowel disease (IBD) and chronic obstructive pulmonary disease (COPD).
DESCRIPTION Tetomilast is a PDE4 inhibitor. Inhibition of PDE4 blocks the oxidative burst in human neutrophils, which is a major mediator of tissue injury in inflammatory diseases. Tetomilast (OPC-6535) was originally identified as an inhibitor of superoxide production by human neutrophils . The clinical potential of PDE4 inhibition in inflammatory bowel disease was reviewed by Salari and Abdollahiin 2012 . (GtoPdb)
DESCRIPTION Tetomilast, a thiazol derivative, has been found to be a PDE-4 inhibitor that could be effective against inflammatory bowel disease by restraining the formation of proinflammatory cytokines and it is still under Phase II trial for chronic obstructive pulmonary disease by Otsuka Pharmaceutical. (BOC Sciences Bioactive Compounds)
Cell lines
0
Organisms
1
Compound Sets
7
BOC Sciences Bioactive Compounds
ChEMBL Drugs
Drug Repurposing Hub
DrugBank
Guide to Pharmacology
MedChem Express Bioactive Compound Library
ReFrame library
External IDs
23
Properties
(calculated by RDKit )
Molecular Weight
370.1
Hydrogen Bond Acceptors
6
Hydrogen Bond Donors
1
Rotatable Bonds
7
Ring Count
3
Aromatic Ring Count
3
cLogP
4.37
TPSA
81.54
Fraction CSP3
0.21
Chiral centers
0.0
Largest ring
6.0
QED
0.67
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Target
PDE4D
Phosphodiesterase (PDE)
MOA
phosphodiesterase inhibitor
Pathway
Metabolic Enzyme/Protease
Source data